Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013.

[1]  Walter A Alarcon.  Summary of Notifiable Noninfectious Conditions and Disease Outbreaks: Elevated Blood Lead Levels Among Employed Adults - United States, 1994-2012. , 2015, MMWR. Morbidity and mortality weekly report.

[2]  E. Briere,et al.  Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). , 2014, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  E. Belongia,et al.  Risk of intussusception after monovalent rotavirus vaccination. , 2014, The New England journal of medicine.

[4]  David Martin,et al.  Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): A Case Study of Febrile Seizures after a 2010–2011 Seasonal Influenza Virus Vaccine , 2013, Drug Safety.

[5]  Jiaquan Xu,et al.  Deaths: final data for 2010. , 2013, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[6]  L. Rubin,et al.  Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale , 2013, MMWR. Morbidity and mortality weekly report.

[7]  Andrea J Cook,et al.  Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. , 2013, American journal of epidemiology.

[8]  David Martin,et al.  Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. , 2012, Vaccine.

[9]  E. Aris,et al.  The safety profile of Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) , 2012, Human vaccines & immunotherapeutics.

[10]  E. Aris,et al.  Immunogenicity and Safety of H influenzae Type b–N meningitidis C/Y Conjugate Vaccine in Infants , 2011, Pediatrics.

[11]  James Singleton,et al.  Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. , 2010, Vaccine.

[12]  M. Pichichero,et al.  Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial , 2009, Pediatrics.

[13]  T. Tapiainen,et al.  Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.

[14]  Jan Bonhoeffer,et al.  Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.

[15]  H. Hense,et al.  Do immunisations reduce the risk for SIDS? A meta-analysis. , 2007, Vaccine.

[16]  E. Mitchell,et al.  Sudden infant death syndrome: no increased risk after immunisation. , 2007, Vaccine.

[17]  S. Black,et al.  A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine , 2005, Expert review of vaccines.

[18]  John Kattwinkel,et al.  The Changing Concept of Sudden Infant Death Syndrome: Diagnostic Coding Shifts, Controversies Regarding the Sleeping Environment, and New Variables to Consider in Reducing Risk , 2005, Pediatrics.

[19]  A. Hayen,et al.  Probability of Coincident Vaccination in the 24 or 48 Hours Preceding Sudden Infant Death Syndrome Death in Australia , 2005, Pediatrics.

[20]  Robert T. Chen,et al.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. , 2004, The Pediatric infectious disease journal.

[21]  R. Davis,et al.  Post-marketing evaluation of the short term safety of COMVAX. , 2004, Vaccine.

[22]  S. Ellenberg,et al.  The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990–1997 , 2001, Pharmacoepidemiology and drug safety.

[23]  Robert T. Chen,et al.  Infant Immunization With Acellular Pertussis Vaccines in the United States: Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS) , 2000, Pediatrics.

[24]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[25]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[26]  E. Rothstein,et al.  Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants. , 1993, American journal of diseases of children.

[27]  K. Edwards,et al.  Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. , 1993, The Journal of pediatrics.

[28]  S. Plotkin,et al.  Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. , 1992, The Journal of pediatrics.

[29]  K. Edwards,et al.  Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. , 1992, The Journal of pediatrics.

[30]  Dl Hoyert,et al.  National Vital Statistics Reports NCHS.pdf , 2012 .

[31]  Donna A. Almario,et al.  Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy , 2003 .

[32]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[33]  A. Rudolph,et al.  Rudolph's Pediatrics , 1969 .